Moclobemide

Pricing Availability Delivery Time Qty
Cat.No. 4395 - Moclobemide | C13H17ClN2O2 | CAS No. 71320-77-9
Description: Reversible MAO-A inhibitor
Chemical Name: 4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide
Purity: ≥99% (HPLC)
Datasheet
Citations
Literature

Biological Activity

Reversible monoamine oxidase A (MOA-A) inhibitor.

Compound Libraries

Moclobemide is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 268.74
Formula C13H17ClN2O2
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 71320-77-9
PubChem ID 4235
InChI Key YHXISWVBGDMDLQ-UHFFFAOYSA-N
Smiles O=C(NCCN2CCOCC2)C1=CC=C(Cl)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 26.87 100
ethanol 26.87 100

Preparing Stock Solutions

The following data is based on the product molecular weight 268.74. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.72 mL 18.61 mL 37.21 mL
5 mM 0.74 mL 3.72 mL 7.44 mL
10 mM 0.37 mL 1.86 mL 3.72 mL
50 mM 0.07 mL 0.37 mL 0.74 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Merck Index 12 6309 PMID:

Burkard et al (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J.Pharmacol.Exp.Ther. 248 391 PMID: 2913284

Prada et al (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J.Pharmacol.Exp.Ther. 248 400 PMID: 2783611


If you know of a relevant reference for Moclobemide, please let us know.

View Related Products by Product Action

View all Monoamine Oxidase Inhibitors

Keywords: reversible monoamine oxidase a moa-a inhibitors inhibits Monoamine Oxidase

Citations for Moclobemide

Citations are publications that use Tocris products.

Currently there are no citations for Moclobemide. Do you know of a great paper that uses Moclobemide from Tocris? If so please let us know.

Commented out for usability testing

Reviews

TODO: Add Reviews

Literature in this Area

Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Addiction

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Pathways for Moclobemide

Protocols

TODO: Add Protocols